Fulcrum Therapeutics (FULC) Current Deferred Revenue (2019 - 2023)

Fulcrum Therapeutics (FULC) has 5 years of Current Deferred Revenue data on file, last reported at $600000.0 in Q3 2023.

• Current Deferred Revenue for Q3 2023 came in at $600000.0, up 50.0% year-over-year; the trailing twelve-month figure through Sep 2023 was $600000.0 (up 50.0% YoY), and the FY2022 annual result was $900000.0, down 71.88% from the prior year.
• Current Deferred Revenue improved to $600000.0 in Q3 2023 per FULC's latest filing, from $513000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $14.9 million in Q4 2020 and troughed at $400000.0 in Q3 2022.
• A 5-year average of $4.1 million and a median of $2.0 million in 2021 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2020 and 2022: Current Deferred Revenue jumped 273.78% in 2020, then sank 89.28% in 2022.
• A 5-year view of Current Deferred Revenue shows it stood at $4.0 million in 2019, then jumped by 273.78% to $14.9 million in 2020, then tumbled by 78.54% to $3.2 million in 2021, then tumbled by 71.88% to $900000.0 in 2022, then tumbled by 33.33% to $600000.0 in 2023.
• Business Quant data shows FULC's Current Deferred Revenue at $600000.0 in Q3 2023, $513000.0 in Q2 2023, and $737000.0 in Q1 2023.